



Expression of Concern: Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan

DOI: 10.7759/cureus.x58

Article published 04/08/2024 Expression of Concern issued 06/12/2024

Miki Gibo ¹, Seiji Kojima ², Akinori Fujisawa ³, Takayuki Kikuchi ⁴, Masanori Fukushima ⁴

1. Primary Health Care, Matsubara Clinic, Kochi, JPN 2. Pediatrics, Nagoya Pediatric Cancer Fund, Nagoya, JPN 3. Cardiovascular Medicine, Honbetsu Cardiovascular Medicine Clinic, Honbetsu, JPN 4. Translational Research & Health Data Science, Learning Health Society Institute, Nagoya, JPN

Corresponding author: Miki Gibo, gibo.578@gmail.com

Corresponding author: Miki Gibo

1. Primary Health Care, Matsubara Clinic, Kochi, JPN 2. Pediatrics, Nagoya Pediatric Cancer Fund, Nagoya, JPN 3. Cardiovascular Medicine, Honbetsu Cardiovascular Medicine Clinic, Honbetsu, JPN 4. Translational Research & Health Data Science, Learning Health Society Institute, Nagoya, JPN

How to cite this expression of concern

Gibo M, Kojima S, Fujisawa A, et al. (June 12, 2024) Expression of Concern: Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan. Cureus 16(6): x58. doi:10.7759/cureus.x58

Expression of Concern

The Editors-in-Chief have been made aware of several concerns regarding the scientific credibility of this article. A comprehensive post-publication editorial review is being conducted to determine if any action is required.